News Johnson & Johnson

Equities

JNJ

US4781601046

Market Closed - Nyse Other stock markets 04:00:02 2024-05-07 pm EDT			After market 06:30:10 pm
148.7 ^USD	+0.09%		149	+0.21%

May. 07	Tylenol maker Kenvue beats quarterly profit estimates, to cut 4% jobs	RE
May. 06	J&J: encouraging results in prostate cancer	CF

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Intravesical drug delivery system exhibits bladder cancer benefit	May. 07	AQ
Tylenol maker Kenvue beats quarterly profit estimates, to cut 4% jobs	May. 07	RE
Johnson & Johnson - Phase 2 data for ERLEADA plus androgen deprivation therapy following radical prostatectomy in patients with high-risk localized prostate cancer show 100% biochemical free recurrence rate	May. 06	AQ
Johnson & Johnson Highlights Commitment to Transform Treatment of Retinal Diseases at ARVO 2024	May. 06	AQ
Johnson & Johnson - TAR-200 monotherapy shows greater than 80% complete response rate in patients with high-risk non-muscle-invasive bladder cancer	May. 06	AQ
J&J: encouraging results in prostate cancer	May. 06	CF
J&J: positive results in bladder cancer	May. 06	CF
Johnson & Johnson Announces Updated Results from an Open-Label, Multicenter, Multi-Cohort Phase 1 Study of the Safety and Efficacy of TAR-210	May. 05	CI
Johnson & Johnson Says Erleada Combination Therapy Achieves 100% BCR-Free Rate	May. 03	MT
Johnson & Johnson Announces Results from the Open-Label, Single-Arm Phase 2 Apa-RP Study Evaluating Adjuvant Treatment with ERLEADA and Androgen Deprivation Therapy	May. 03	CI
Johnson & Johnson submits regulatory applications to European Medicines Agency for TREMFYA (guselkumab) for treatment of patients with ulcerative colitis and Crohn's disease	May. 03	AQ
Johnson & Johnson Announces Plan by its Subsidiary, LLT Management LLC, to Resolve All Current and Future Ovarian Cancer Talc Claims Through a Consensual 'Prepackaged' Reorganization	May. 03	AQ
Johnson & Johnson Announces Updated Results from Cohort 2 of the Phase 2b SunRISe-1 Study Evaluating the Efficacy and Safety of Investigational TAR-200 Monotherapy	May. 03	CI
J&J: to present advances in retinal diseases	May. 03	CF
Johnson & Johnson Highlights Commitment to Transform Treatment of Retinal Diseases at ARVO 2024	May. 03	CI
Global markets live: Etsy, Qualcomm, Carvana, Rio Tinto, Apple...	May. 02
J&J: applies to the EMA for an extended MA for Tremfya	May. 02	CF
Johnson & Johnson : 2024 First-Quarter Press Release & Supplemental Schedules (April 16, 2024)	May. 02	PU
Johnson & Johnson : Announces Plan by its Subsidiary, LLT Management LLC, to Resolve All Current and Future Ovarian Cancer Talc Claims Through a Consensual “Prepackaged” Reorganization Press Release	May. 02	PU
Sector Update: Health Care Stocks Rise Late Afternoon	May. 01	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Joseph Wolk, CFO of J&J: End of patent for its flagship drug

January 23, 2024 at 12:30 pm EST